# NEOPAC (NCT01314027)

> Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer

No report yet. It can be ordered.

- Drugs tested: gemcitabine plus oxaliplatin
- Indication: resectable pancreatic cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01314027
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: University of Zurich
- Conditions: Pancreatic Cancer
- Interventions: Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin; adjuvant chemotherapy with gemcitabine
- Enrollment: 38
- Primary outcome: Progression-free survival

## Indexed commentary on NEOPAC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=neopac-nct01314027